Kansas City, KANSAS3 Active Studies

Multiple Sclerosis Clinical Trials in Kansas City, KANSAS

Find 3 actively recruiting multiple sclerosis clinical trials in Kansas City, KANSAS. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
595
Enrolling

Recruiting Multiple Sclerosis Studies in Kansas City

About Multiple Sclerosis Clinical Trials in Kansas City

Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the protective covering of nerve fibers, causing communication problems between the brain and body. Symptoms vary widely and can include vision problems, fatigue, and mobility issues. Disease-modifying therapies have significantly improved outcomes.

There are currently 3 multiple sclerosis clinical trials recruiting participants in Kansas City, KANSAS. These studies are seeking a combined 595 participants. Research is being sponsored by Biogen, Celgene, University of Kansas Medical Center. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Sclerosis Clinical Trials in Kansas City — FAQ

Are there multiple sclerosis clinical trials in Kansas City?

Yes, there are 3 multiple sclerosis clinical trials currently recruiting in Kansas City, KANSAS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Kansas City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Kansas City research site will contact you about next steps.

Are clinical trials in Kansas City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Kansas City studies also compensate for your time and travel.

What multiple sclerosis treatments are being tested?

The 3 active trials in Kansas City are testing new therapies including novel drugs, biologics, and treatment approaches for multiple sclerosis.

Data updated March 2, 2026 from ClinicalTrials.gov